-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, researchers from Martin Luther Haller Wittenberg University (MLU) and Graveswald University in Germany have developed a new inhibitor that can make drug-resistant tumor cells respond to chemotherapy again.
In addition to radiation therapy, cytotoxic drugs (ie chemotherapy) are also often used to treat cancer.
Hilgeroth's research team has now developed a new class of substances that can inhibit one of these transport proteins: multidrug resistance protein 4 (MRP4).
Hilgeroth explained that the new substances may have two positive effects at the same time: “stop the transmission of cancer-promoting messengers and ensure that chemotherapy is effective again.
Now, the compound's efficacy must be confirmed in further preclinical trials.
Original source: Henry Döring et al, Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy, Molecules (2020).